These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26912444)

  • 1. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
    Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
    J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.
    Kwee SA; Lim J; Watanabe A; Kromer-Baker K; Coel MN
    J Nucl Med; 2014 Jun; 55(6):905-10. PubMed ID: 24676753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of
    Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G
    Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer.
    Nozaki K; Kawai T; Fujimura T; Matsui H; Teshima T; Oshina T; Takahashi A; Sato Y; Yamada D; Azuma T; Hotta M; Nakajima K; Nakayama H; Minamimoto R; Kume H
    Int Urol Nephrol; 2019 Oct; 51(10):1763-1769. PubMed ID: 31325132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
    Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
    Kwee SA; Lim J; Coel MN
    Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
    Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
    Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Skeletal Tumor Activity on (18)F-choline PET/CT in Patients Receiving (223)Radium Radionuclide Therapy for Metastatic Prostate Cancer.
    Miyazaki KS; Kuang Y; Kwee SA
    Nucl Med Mol Imaging; 2015 Jun; 49(2):160-4. PubMed ID: 26082811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    De Giorgi U; Caroli P; Burgio SL; Menna C; Conteduca V; Bianchi E; Fabbri F; Carretta E; Amadori D; Paganelli G; Matteucci F
    Oncotarget; 2014 Dec; 5(23):12448-58. PubMed ID: 25504434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of [
    Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Alamiri J; Britton CJ; Ahmed ME; Andrews JR; Higa JL; Dundar A; Karnes RJ; Kwon E; Lowe VJ; Kendi AT; Bold MS; Pagliaro LC
    Prostate; 2022 Dec; 82(16):1483-1490. PubMed ID: 36089822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim and end-treatment
    García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
    Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Trial of
    Wang B; Liu C; Wei Y; Meng J; Zhang Y; Gan H; Xu X; Wan F; Pan J; Ma X; Hu S; Freedland SJ; Song S; Ye D; Zhu Y
    Clin Cancer Res; 2020 Sep; 26(17):4551-4558. PubMed ID: 32527944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Jimbo M; Andrews JR; Ahmed ME; Dundar A; Karnes RJ; Bryce AH; Kendi AT; Kwon ED; Lowe VJ; Bold MS
    Prostate; 2022 Jan; 82(1):41-48. PubMed ID: 34633087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.